Although the results of the TRYPHAENA trial were published in 2013 [33], we were unable to use a HER2 blockade in our current neoadjuvant setting and study period because of the reimbursement policy of the Korean National Health Insurance system for locally advanced breast cancer. The gene discussed is ERBB2; the disease is breast cancer.